Combination opioid agonist/antagonist therapy has been shown to preserve bowel function in patients with chronic cancer pain. This retrospective study evaluated the efficacy and tolerability of prolonged-released fixed-dose oxycodone-naloxone (PR OXN) in consecutive outpatients with chronic cancer pain. Of 206 patients prescribed PR OXN (mean age 61.3 ± 12.9 years; 52.9% female), 31.5% were opioid naïve. PR OXN was associated with a significant decrease in pain score measured on a visual analogue scale over 28 days (P < .0001), without adverse effects on bowel function, nor change in laxative use. PR OXN efficacy and tolerability were similar in opioid-naïve and -experienced patients, and among age-stratified subgroups. No severe side effects occurred. In a real-life outpatient setting, PR OXN provided analgesia without bowel dysfunction in patients with chronic cancer pain.
RipamontiCISantiniDMaranzanoEBertiMRoilaF. Management of cancer pain: ESMO clinical practice guidelines. Ann Oncol. 2012;23suppl 7:vii139–vii154.
2.
CaraceniAHanksGKaasaS. Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. Lancet Oncol. 2012;13(2):e58–e68.
3.
DeandreaSMontanariMMojaLApoloneG. Prevalence of undertreatment in cancer pain. a review of published literature. Ann Oncol. 2008;19(12):1985–1991.
4.
BreivikHChernyNCollettB. Cancer-related pain: a pan-European survey of prevalence, treatment, and patient attitudes. Ann Oncol. 2009;20(8):1420–1433.
5.
CandyBJonesLGoodmanMLDrakeRTookmanA. Laxatives or methylnaltrexone for the management of constipation in palliative care patients. Cochrane Database Syst Rev. 2011;(1):CD003448.
6.
ClemensKEQuednauIKlaschikE. Bowel function during pain therapy with oxycodone/naloxone prolonged-release tablets in patients with advanced cancer. Int J Clin Pract. 2011;65(4):472–478.
7.
DunlopWUhlRKhanITaylorABartonG. Quality of life benefits and cost impact of prolonged release oxycodone/naloxone versus prolonged release oxycodone in patients with moderate-to-severe non-malignant pain and opioid-induced constipation: a UK cost-utility analysis. J Med Econ. 2012;15(3):564–575.
8.
CamilleriM. Opioid-induced constipation: challenges and therapeutic opportunities. Am J Gastroenterol. 2011;106(5):835–842; quiz 843.
9.
CaraceniAPigniABrunelliC. Is oral morphine still the first choice opioid for moderate to severe cancer pain? A systematic review within the European palliative care research collaborative guidelines project. Palliat Med. 2011;25(5):402–409.
10.
KingSJReidCForbesKHanksG. A systematic review of oxycodone in the management of cancer pain. Palliat Med. 2011;25(5):454–470.
11.
ReidCMMartinRMSterneJADaviesANHanksGW. Oxycodone for cancer-related pain: meta-analysis of randomized controlled trials. Arch Intern Med. 2006;166(8):837–843.
12.
WeschulesDJBainKTReifsnyderJ. Toward evidence-based prescribing at end of life: a comparative analysis of sustained-release morphine, oxycodone, and transdermal fentanyl, with pain, constipation, and caregiver interaction outcomes in hospice patients. Pain Med. 2006;7(4):320–329.
13.
LeppertW. The role of opioid receptor antagonists in the treatment of opioid-induced constipation: a review. Adv Ther. 2010;27(10):714–730.
14.
HolzerP. Opioid antagonists for prevention and treatment of opioid-induced gastrointestinal effects. Curr Opin Anaesthesiol. 2010;23(5):616–622.
15.
GattiASabatoAF. Management of opioid-induced constipation in cancer patients: focus on methylnaltrexone. Clin Drug Investig. 2012;32(5):293–301.
16.
LowensteinOLeyendeckerPHoppM. Combined prolonged-release oxycodone and naloxone improves bowel function in patients receiving opioids for moderate-to-severe non-malignant chronic pain: a randomised controlled trial. Expert Opin Pharmacother. 2009;10(4):531–543.
17.
VondrackovaDLeyendeckerPMeissnerW. Analgesic efficacy and safety of oxycodone in combination with naloxone as prolonged release tablets in patients with moderate to severe chronic pain. J Pain. 2008;9(12):1144–1154.
18.
SimpsonKLeyendeckerPHoppM. Fixed-ratio combination oxycodone/naloxone compared with oxycodone alone for the relief of opioid-induced constipation in moderate-to-severe noncancer pain. Curr Med Res Opin. 2008;24(12):3503–3512.
19.
MeissnerWLeyendeckerPMueller-LissnerS. A randomised controlled trial with prolonged-release oral oxycodone and naloxone to prevent and reverse opioid-induced constipation. Eur J Pain. 2009;13(1):56–64.
20.
AhmedzaiSHNauckFBar-SelaGBosseBLeyendeckerPHoppM. A randomized, double-blind, active-controlled, double-dummy, parallel-group study to determine the safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate/severe, chronic cancer pain. Palliat Med. 2012;26(1):50–60.
21.
SchutterUGrunertSMeyerCSchmidtTNolteT. Innovative pain therapy with a fixed combination of prolonged-release oxycodone/naloxone: a large observational study under conditions of daily practice. Curr Med Res Opin. 2010;26(6):1377–1387.
22.
ShaheenPEWalshDLasheenWDavisMPLagmanRL. Opioid equianalgesic tables: are they all equally dangerous?J Pain Symptom Manage. 2009;38(3):409–417.
23.
PatanwalaAEDubyJWatersDErstadBL. Opioid conversions in acute care. Ann Pharmacother. 2007;41(2):255–266.
24.
RentzAMvan Hanswijck de JongePLeyendeckerPHoppM. Observational, nonintervention, multicenter study for validation of the Bowel Function Index for constipation in European countries. Curr Med Res Opin. 2011;27(1):35–44.
25.
RentzAMYuRMuller-LissnerSLeyendeckerP. Validation of the Bowel Function Index to detect clinically meaningful changes in opioid-induced constipation. J Med Econ. 2009;12(4):371–383.
26.
UeberallMAMuller-LissnerSBuschmann-KrammCBosseB. The Bowel Function Index for evaluating constipation in pain patients: definition of a reference range for a non-constipated population of pain patients. J Int Med Res. 2011;39(1):41–50.
27.
ClemensKEKlaschikE. Management of constipation in palliative care patients. Curr Opin Support Palliat Care. 2008;2(1):22–27.
28.
LowensteinOLeyendeckerPLuxEA. Efficacy and safety of combined prolonged-release oxycodone and naloxone in the management of moderate/severe chronic non-malignant pain: results of a prospectively designed pooled analysis of two randomised, double-blind clinical trials. BMC Clin Pharmacol. 2010;10:12.
29.
CloutierCTalianoJO’MahonyW. Controlled-release oxycodone and naloxone in the treatment of chronic low back pain: a placebo-controlled, randomized study. Pain Res Manag. 2013;18(2):75–82.
30.
FarrarJTYoungJPJrLaMoreauxLWerthJLPooleRM. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain. 2001;94(2):149–158.
31.
MercadanteSPorzioGFerreraPAielliFAdileCFicorellaC. Low doses of transdermal fentanyl in opioid-naive patients with cancer pain. Curr Med Res Opin. 2010;26(12):2765–2768.
32.
MercadanteSPorzioGFerreraP. Tapentadol in cancer pain management: a prospective open-label study. Curr Med Res Opin. 2012;28(11):1775–1779.
33.
MercadanteSPorzioGFerreraP. Low doses of transdermal buprenorphine in opioid-naive patients with cancer pain: a 4-week, nonrandomized, open-label, uncontrolled observational study. Clin Ther. 2009;31(10):2134–2138.
34.
MercadanteSPorzioGFerreraP. Low morphine doses in opioid-naive cancer patients with pain. J Pain Symptom Manage. 2006;31(3):242–247.
35.
LarkinPJSykesNPCentenoC. The management of constipation in palliative care: clinical practice recommendations. Palliat Med. 2008;22(7):796–807.
36.
BellTJPanchalSJMiaskowskiCBolgeSCMilanovaTWilliamsonR. The prevalence, severity, and impact of opioid-induced bowel dysfunction: results of a US and European patient survey (PROBE 1). Pain Med. 2009;10(1):35–42.
37.
DaleOMoksnesKKaasaS. European palliative care research collaborative pain guidelines: opioid switching to improve analgesia or reduce side effects. A systematic review. Palliat Med. 2011;25(5):494–503.
38.
Mueller-LissnerS. Fixed combination of oxycodone with naloxone: a new way to prevent and treat opioid-induced constipation. Adv Ther. 2010;27(9):581–590.
39.
ThomasJKarverSCooneyGA. Methylnaltrexone for opioid-induced constipation in advanced illness. N Engl J Med. 2008;358(22):2332–2343.
40.
SilvermanSL. From randomized controlled trials to observational studies. Am J Med. 2009;122(2):114–120.
